Zoetis Inc. logo

Zoetis Inc.

ZTS

NYSEHealthcareDrug Manufacturers - Specialty & Generic

Previous close

$77.74

+$2.72 · +3.63%

Aug 21, 3:59 PM ET

Pre-market

$78.44

+$0.70 · +0.90%

Aug 24, 6:36 AM ET

ZTS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

96

Deep Value

Momentum

25

Weakening

Sentiment

66

Bullish

Risk resilience

57

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
US
CEO
Kristin C. Peck
Listed since
Feb 1, 2013
Employees
14,500

Market position

Day range

Current $77.74

52-week range

Current $77.74

Open
$75.29
Previous close
$75.02
Volume
4.39M
0.63× average
Average volume
6.99M
Average daily volume
Market cap
32.59B USD
Beta
0.73
Market reference 1
50-day average
$76.0074
+2.28% above average
200-day average
$105.57
-26.36% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
62.97B USD
EV / EBITDA
15.48×
Earnings yield
4.79%
Free cash flow yield
4.09%

Profitability & efficiency

Return on equity
80.25%
Return on assets
17.28%
Return on invested capital
21.54%

Financial health

Current ratio
3.03×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends75%57%39%22%Gross margin, FY2021: 68.31%Gross margin, FY2022: 67.77%Gross margin, FY2023: 68.28%Gross margin, FY2024: 69.10%Gross margin, FY2025: 70.49%Operating margin, FY2021: 36.05%Operating margin, FY2022: 36.24%Operating margin, FY2023: 35.92%Operating margin, FY2024: 36.65%Operating margin, FY2025: 38.00%Net margin, FY2021: 26.20%Net margin, FY2022: 26.16%Net margin, FY2023: 27.43%Net margin, FY2024: 26.86%Net margin, FY2025: 28.23%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 68.31%. Gross margin FY2022 67.77%. Gross margin FY2023 68.28%. Gross margin FY2024 69.10%. Gross margin FY2025 70.49%. Operating margin FY2021 36.05%. Operating margin FY2022 36.24%. Operating margin FY2023 35.92%. Operating margin FY2024 36.65%. Operating margin FY2025 38.00%. Net margin FY2021 26.20%. Net margin FY2022 26.16%. Net margin FY2023 27.43%. Net margin FY2024 26.86%. Net margin FY2025 28.23%.

Income trends

Revenue

9.47B USD+2.28%

Operating income

3.6B USD+6.04%

Net income

2.67B USD+7.52%
Income trends across reported periods10.21B USD7.24B USD4.27B USD1.29B USDRevenue, FY2021: 7.78B USDRevenue, FY2022: 8.08B USDRevenue, FY2023: 8.54B USDRevenue, FY2024: 9.26B USDRevenue, FY2025: 9.47B USDOperating income, FY2021: 2.8B USDOperating income, FY2022: 2.93B USDOperating income, FY2023: 3.07B USDOperating income, FY2024: 3.39B USDOperating income, FY2025: 3.6B USDNet income, FY2021: 2.04B USDNet income, FY2022: 2.11B USDNet income, FY2023: 2.34B USDNet income, FY2024: 2.49B USDNet income, FY2025: 2.67B USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 7.78B USD. Revenue FY2022 8.08B USD. Revenue FY2023 8.54B USD. Revenue FY2024 9.26B USD. Revenue FY2025 9.47B USD. Operating income FY2021 2.8B USD. Operating income FY2022 2.93B USD. Operating income FY2023 3.07B USD. Operating income FY2024 3.39B USD. Operating income FY2025 3.6B USD. Net income FY2021 2.04B USD. Net income FY2022 2.11B USD. Net income FY2023 2.34B USD. Net income FY2024 2.49B USD. Net income FY2025 2.67B USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue9.47B USD9.26B USD8.54B USD8.08B USD7.78B USD
Cost of goods sold2.79B USD2.86B USD2.71B USD2.6B USD2.46B USD
Gross profit6.67B USD6.4B USD5.83B USD5.48B USD5.31B USD
Research and development698M USD686M USD614M USD539M USD508M USD
Selling, general, and administrative2.38B USD2.32B USD2.15B USD2.01B USD2B USD
Operating expenses3.08B USD3B USD2.77B USD2.55B USD2.51B USD
Interest income93M USD106M USD105M USD50M USD6M USD
Interest expense243M USD242M USD258M USD237M USD236M USD
Depreciation and amortization487M USD497M USD491M USD465M USD448M USD
Operating income3.6B USD3.39B USD3.07B USD2.93B USD2.8B USD
Net income2.67B USD2.49B USD2.34B USD2.11B USD2.04B USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
82%
9 beats, 2 misses, 0 met estimates
Average EPS surprise
+3.00%
11 comparable reports
Latest EPS result
1.87
Estimate 1.85 · Beat by 1.08%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.941.731.511.3Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 13, 2025: actual 1.4, estimate 1.37, surprise +2.19%, Beat. Q2 2025, reported May 6, 2025: actual 1.48, estimate 1.41, surprise +4.96%, Beat. Q3 2025, reported Aug 5, 2025: actual 1.76, estimate 1.62, surprise +8.64%, Beat. Q4 2025, reported Nov 4, 2025: actual 1.7, estimate 1.62, surprise +4.94%, Beat. Q1 2026, reported Feb 12, 2026: actual 1.48, estimate 1.4, surprise +5.71%, Beat. Q2 2026, reported May 7, 2026: actual 1.53, estimate 1.6, surprise -4.38%, Miss. Q3 2026, reported Aug 6, 2026: actual 1.87, estimate 1.85, surprise +1.08%, Beat. Q4 2026, reported Nov 3, 2026: actual —, estimate 1.53, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates2.6B2.43B2.26B2.09BQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 13, 2025: actual 2.32B USD, estimate 2.3B USD, surprise +0.86%, Beat. Q2 2025, reported May 6, 2025: actual 2.22B USD, estimate 2.19B USD, surprise +1.37%, Beat. Q3 2025, reported Aug 5, 2025: actual 2.46B USD, estimate 2.41B USD, surprise +2.10%, Beat. Q4 2025, reported Nov 4, 2025: actual 2.4B USD, estimate 2.41B USD, surprise -0.41%, Miss. Q1 2026, reported Feb 12, 2026: actual 2.39B USD, estimate 2.36B USD, surprise +1.14%, Beat. Q2 2026, reported May 7, 2026: actual 2.26B USD, estimate 2.3B USD, surprise -1.71%, Miss. Q3 2026, reported Aug 6, 2026: actual 2.47B USD, estimate 2.5B USD, surprise -1.34%, Miss. Q4 2026, reported Nov 3, 2026: actual —, estimate 2.31B USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$98.33

26.49% upside
Past 12 months12-month forecast

Price history unavailable

High $160Average $98.33Low $80.00

Rating distribution

32 ratings
Strong buy13%
Buy1444%
Hold1753%
Sell00%
Strong sell00%

ZTS news

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

$2.00

2025 complete year+100.0% since 2021

2026 partial: $1.59

* Partial calendar year in the available dividend history.

Corporate action history

Dividend

Ex-dividend Jul 20, 2026

$0.53

Quarterly

Record Jul 20, 2026 · Payment Sep 1, 2026

Dividend

Ex-dividend Apr 20, 2026

$0.53

Quarterly

Record Apr 20, 2026 · Payment Jun 2, 2026

Dividend

Ex-dividend Jan 20, 2026

$0.53

Quarterly

Record Jan 20, 2026 · Payment Mar 3, 2026

Dividend

Ex-dividend Oct 31, 2025

$0.50

Quarterly

Record Oct 31, 2025 · Payment Dec 2, 2025

Dividend

Ex-dividend Jul 18, 2025

$0.50

Quarterly

Record Jul 18, 2025 · Payment Sep 3, 2025

Dividend

Ex-dividend Apr 21, 2025

$0.50

Quarterly

Record Apr 21, 2025 · Payment Jun 3, 2025

ZTS peers

ETFs holding ZTS

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research ZTS

research.disclaimer